InnoDiab Forschung GmbH

Essen 31 trials 6 recruiting

31 Registered trials

6 Currently recruiting

Organisation

InnoDiab Forschung GmbH

Location

Essen, Germany

Identifier

ORG-100040195

Address

Eleonorastrasse 42, Ruettenscheid, 45136, Germany

Departments

-
InnoDiab
InnoDiab Forschung GmbH
internal medicine, diabetology
N/A
NA
Practice
private practice

Clinical trials at this site (31)

Search interface

A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting

2025-523106-32-00 Obesity or Overweight and Type 2 Diabetes 5 2026-05-25
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting

2025-523104-71-00 Obesity or Overweight Without Type 2 Diabetes 5 2026-05-08
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting

2025-523657-34-00 Obesity 5 2026-04-13
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-… Recruiting

2025-522703-14-00 "Moderate to severe obstructive sleep apnea (OSA) in ad 5 2026-02-17
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Recruiting

2024-520328-27-00 Type 2 Diabetes 4 2025-08-07
Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended

2024-519530-24-00 Overweight and obesity 5 2025-10-31
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi… Ended

2024-519945-31-00 Type 1 Diabetes 5 2025-08-21
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2… Ended

2025-521098-14-00 GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes 5 2025-08-15
A Study of Tirzepatide (LY3298176) Compared with Placebo in Adults with Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) Ended

2024-519684-17-00 Obesity 5 2025-06-23
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) Ended

2024-515905-25-00 Overweight or Obesity 5 2025-01-29
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended

2024-511450-49-00 Obesity 5 2024-10-22
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Overweight and obesity 5 2022-10-17
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M… Ended

2024-512562-34-00 Type 2 Diabetes Mellitus 4 2025-02-24
A weight loss study evaluating subcutaneous treatment withAZD9550 and AZD6234 in combination, against placebo or each of the drugs alone Ended

2024-516176-15-00 Investigating obesity or overweight condition correlate 4 2025-02-24
A research study to see how well different doses of CagriSema help people with excess body weight lose weight Ended

2023-509273-24-00 Obesity 5 2024-09-05
A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended

2023-509412-28-00 Type 2 Diabetes 4 2024-07-26
A Research Study to See How Switching from a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar … Ended

2023-506084-34-00 Type 2 Diabetes 5 2024-04-12
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W… Ended

2023-507206-13-00 Type 2 Diabetes 5 2024-03-14
A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys’ ability … Ended

2022-503024-27-00 Chronic kidney disease associated with type 1 diabetes 5 2024-02-27
A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended

2022-502529-17-00 Obesity 5 2024-01-18